CClinicalTrials.gg
Status unknownNCT00434902ETENDARDUpdated Dec 19, 2012

Evaluation of the Prevalence of Pulmonary Hypertension in Adult Patients With Sickle Cell Disease

An observational study in Sickle Cell Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-19.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

The sponsor has not verified this record recently (last verified Nov 2012), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
18 Years and older
Sex
All
01

Study summary

Recent data show that pulmonary hypertension (PH), defined by a tricuspid regurgitation jet (TRJ) velocity > or equal at 2.5m/s on Doppler echocardiography, is present in about 30% of adults with sickle cell disease (SCD) and is associated with poor prognosis. However in SCD the occurrence of PH (defined by mean pulmonary arterial pressure (mPAP)> or equal at 25 mmHg) is related to at least 3 mechanisms: PH due to hyperkinetic state with high cardiac output (CO) but normal pulmonary vascular resistance (PVR \<160 dynes), or postcapillary PH (pulmonary capillary wedge pressure PCWP >15 mmHg), or precapillary pulmonary arterial hypertension (PAH) defined by mPAP > or equal at 25 mmHg, PCWP\< or equal at 15 mmHg and PVR > or equal at 160 dynes.The aim of this study is to evaluate in a French population of adults with sickle cell disease the characteristics, prevalence and prognosis of pulmonary hypertension.

Read the detailed description

Consecutive adult patients with sickle cell disease (SCD) had a Doppler echocardiography to evaluate if they had a suspected pulmonary hypertension (PH) on the basis of a tricuspid regurgitation jet (TRJ) velocity > or equal at 2.5m/s. In this case, a right heart catheterization was performed to confirm or not this diagnosis and its mechanisms. Each included patient was followed every year for 3 years: during each visit, a clinical evaluation was obtained and a Doppler echocardiography. In case of emergence of a suspected PH, a right heart catheterization was performed to confirm or not this diagnosis and its mechanisms.

Three groups of patients were defined: no PH, precapillary PH, and a third group including post-capillary PH and hyperkinetic state. These groups were well defined on the basis of the results of th Doppler echocardiography and right heart catheterisation.

Characteristics of patients and their prognosis were evaluated in each group.

In the same, way, biological study is planned to evaluate some biological markers of the mechanism of PH, and prognostic factors.

02

Conditions studied

  • Sickle Cell Disease

Keywords

  • Doppler Echocardiography
  • Pulmonary hypertension
  • Sickle cell disease
03

In context

Hypertension, Pulmonary

1,105 studies on the registry are indexed under Hypertension, Pulmonary; 234 are open to participants now.

This study's planned enrollment of 700 is above the median of 116 across 386 observational studies indexed under Hypertension, Pulmonary.

Browse Hypertension, Pulmonary studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult Patients With Sickle Cell Disease

Inclusion criteria

  • Homozygous SS sickle cell disease
  • Male or female > 18 years of age
  • VOC (Vaso-Occlusive crisis) or ACS (Acute chest syndrome)within 6 weeks of inclusion ("Stable state")
  • Signed written Informed consent

Exclusion criteria

Exclusion Criteria:

  • Creatinine clearance \< 30 ml/mn
  • prothrombin ratio \< 50%
  • Severe pneumopathy and TLC (Total lung capacity) \< 70%
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
06

Study locations

1 site
  • Hôpital Antoine Béclère
    Clamart, 92141, France
07

References and documents

Publications

  • Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):5S-12S. doi: 10.1016/j.jacc.2004.02.037. PubMed 15194173 ↗
  • Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar 21;346(12):896-903. doi: 10.1056/NEJMoa012212. Erratum In: N Engl J Med 2002 Apr 18;346(16):1258. PubMed 11907289 ↗
  • Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004 Sep 30;351(14):1425-36. doi: 10.1056/NEJMra040291. No abstract available. PubMed 15459304 ↗
  • Lechapt E, Habibi A, Bachir D, Galacteros F, Schaeffer A, Desvaux D, Brochard L, Housset B, Godeau B, Maitre B. Induced sputum versus bronchoalveolar lavage during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2003 Dec 1;168(11):1373-7. doi: 10.1164/rccm.200302-174OC. Epub 2003 Sep 11. PubMed 12969866 ↗
  • Maitre B, Habibi A, Roudot-Thoraval F, Bachir D, Belghiti DD, Galacteros F, Godeau B. Acute chest syndrome in adults with sickle cell disease. Chest. 2000 May;117(5):1386-92. doi: 10.1378/chest.117.5.1386. PubMed 10807826 ↗
  • Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, Habibi A, Bennani S, Savale L, Adnot S, Maitre B, Yaici A, Hajji L, O'Callaghan DS, Clerson P, Girot R, Galacteros F, Simonneau G. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med. 2011 Jul 7;365(1):44-53. doi: 10.1056/NEJMoa1005565. PubMed 21732836 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00434902
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Feb 14, 2007
Start date
Feb 2007
Primary completion
Mar 2009
Completion
Dec 2012 (estimated)
Last update
Dec 19, 2012

Study contacts

Gerald SIMONNEAU, MD
principal investigator · Hôpital Antoine Béclère, CLAMART
Frederic Galacteros, MD
principal investigator · Hôpital Henri Mondor, Creteil
Serge ADNOT, MD
study director · Hôpital Henri Mondor, CRETEIL
Bernard MAITRE, MD
study director · Hopital Henri Mondor, CRETEIL
Marc HUMBERT, MD
study director · Hôpîtal Antoine Béclere, CLAMART
Robert GIROT, MD
study director · Hôpital Tenon, PARIS
François LIONNET, MD
study director · Hôpital TENON, PARIS
Françoise DRISS, MD
study director · Hôpital Bicêtre, KREMLIN BICETRE
Olivier LAMBOTTE, MD
study chair · Hôpital Bicêtre, KREMLIN BICETRE
Jocelyn INAMO, MD
study director · CHU Fort de France
Gylna LOKO, MD
study director · CHU Fort de France
Olivier SITBON, MD
study director · Hôpital Antoine Béclère, CLAMART
Xavier Jaïs, MD
study director · Hôpital Antoine Béclère, CLAMART
Anoosha Habibi, MD
study chair · Hôpital Henri Mondor, CRETEIL
Dora Bachir, MD
study chair · Hôpital Henri Mondor, CRETEIL
Laurent SAVALE, MD
study chair · Hopital Henri Mondor, CRETEIL
Saadia Eddahibi, MD
study chair · Hôpital Henri Mondor, CRETEIL
Gilles Garcia, MD
study chair · Hopital Antoine Béclère, CLAMART

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion